Cytokine regulation networks in the cancer microenvironment.

During carcinoma formation, cancer cells release various cytokines and growth factors into their surroundings and recruit and reprogram many other types of cells in order to establish a tumor microenvironment. Consequently, the tumor tissues almost always contain a large number of endothelial cells, fibroblasts, and infiltrating inflammatory cells that in turn produce a variety of cytokines. The cytokines produced by these cells have been posited as key factors in modulating immune response either against or in favor of tumorigenesis in the microenvironment. The interactions that take place between immune and cancer cells are complex, involving multiple cascades of cytokines, chemokines, and/or growth factors. In this review, we address the essential pro- and anti-tumorigenic roles of cytokines in the tumor microenvironment. As the interaction of cytokines, growth factors, and cancer cells forms a comprehensive network at the tumor site that is then responsible for the overall progression or rejection of the tumor, the current review links the microenvironment-derived cytokines and growth factors to a number of different kinds of human carcinogenesis models. Multifunctional cytokines, extracellular matrix mediators, and regulatory cytokines in the cancer environment are all shown to be key factors in the different cancer immune-editing systems. The characterization of cytokine networks in various types of cancer cells may yield important information for understanding the immune-related mechanisms of cancer development, and this knowledge may have subsequent application in cancer immunotherapy.

[1]  R. Bonavia,et al.  Stromal Cell-derived Factor 1α Stimulates Human Glioblastoma Cell Growth through the Activation of Both Extracellular Signal-regulated Kinases 1/2 and Akt , 2003 .

[2]  L. Wakefield,et al.  TGF-beta switches from tumor suppressor to prometastatic factor in a model of breast cancer progression. , 2003, The Journal of clinical investigation.

[3]  C. Roussos,et al.  Tumor Necrosis Factor-α Promotes Malignant Pleural Effusion , 2007 .

[4]  Cheng Dong,et al.  Targeting Mutant V600EB‐Raf in Melanoma Interrupts Immunoediting of Leukocyte Functions and Melanoma Extravasation , 2007, Cancer research.

[5]  A. Lindén,et al.  Interleukin-17 family members and inflammation. , 2004, Immunity.

[6]  B. Sheu,et al.  A novel role of metalloproteinase in cancer-mediated immunosuppression. , 2001, Cancer research.

[7]  Y. Ben-Neriah,et al.  NF-κB functions as a tumour promoter in inflammation-associated cancer , 2004, Nature.

[8]  H. Weiner,et al.  Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells , 2006, Nature.

[9]  J. Chirgwin,et al.  The human Cyr61 gene is a transcriptional target of transforming growth factor beta in cancer cells. , 2007, Cancer letters.

[10]  G. Trinchieri,et al.  Interleukin-12 and the regulation of innate resistance and adaptive immunity , 2003, Nature Reviews Immunology.

[11]  Penny A. Johnson,et al.  Mechanisms of local immunosuppression in cutaneous melanoma , 2007, British Journal of Cancer.

[12]  B. Sheu,et al.  Predominant Th2/Tc2 Polarity of Tumor-Infiltrating Lymphocytes in Human Cervical Cancer1 , 2001, The Journal of Immunology.

[13]  H. Nakshatri,et al.  NF-κ B Promotes Breast Cancer Cell Migration and Metastasis by Inducing the Expression of the Chemokine Receptor CXCR4* , 2003, Journal of Biological Chemistry.

[14]  T. Malek,et al.  Tolerance, not immunity, crucially depends on IL-2 , 2004, Nature Reviews Immunology.

[15]  P. Carmeliet,et al.  Dendritic Cell Subsets Differentially Regulate Angiogenesis in Human Ovarian Cancer , 2004, Cancer Research.

[16]  Y. Shyr,et al.  Enhanced hepatocyte growth factor signaling by type II transforming growth factor-beta receptor knockout fibroblasts promotes mammary tumorigenesis. , 2007, Cancer research.

[17]  R. Schreiber,et al.  A critical function for type I interferons in cancer immunoediting , 2005, Nature Immunology.

[18]  M. Ratajczak,et al.  Trafficking of Normal Stem Cells and Metastasis of Cancer Stem Cells Involve Similar Mechanisms: Pivotal Role of the SDF‐1–CXCR4 Axis , 2005, Stem cells.

[19]  Wen‐Chun Chang,et al.  Immune concept of human papillomaviruses and related antigens in local cancer milieu of human cervical neoplasia , 2007, The journal of obstetrics and gynaecology research.

[20]  D. Jablons,et al.  A novel in vitro model of human mesothelioma for studying tumor biology and apoptotic resistance. , 2005, American journal of respiratory cell and molecular biology.

[21]  G. Watkins,et al.  Stromal cell derived factor-1: its influence on invasiveness and migration of breast cancer cells in vitro, and its association with prognosis and survival in human breast cancer , 2005, Breast Cancer Research.

[22]  T. Whiteside,et al.  Immune suppression in cancer: effects on immune cells, mechanisms and future therapeutic intervention. , 2006, Seminars in cancer biology.

[23]  H. Moses,et al.  Stromal fibroblasts in cancer initiation and progression , 2004, Nature.

[24]  J. Carucci,et al.  Human basal cell carcinoma is associated with Foxp3+ T cells in a Th2 dominant microenvironment. , 2007, The Journal of investigative dermatology.

[25]  R. Lechler,et al.  The maintenance of human CD4+ CD25+ regulatory T cell function: IL-2, IL-4, IL-7 and IL-15 preserve optimal suppressive potency in vitro. , 2007, International immunology.

[26]  I. Fidler,et al.  Regulation of neoplastic angiogenesis. , 2000, Journal of the National Cancer Institute. Monographs.

[27]  T. Whiteside,et al.  Expansion and characteristics of human T regulatory type 1 cells in co-cultures simulating tumor microenvironment , 2007, Cancer Immunology, Immunotherapy.

[28]  S. Zheng,et al.  IL-2 Is Essential for TGF-β to Convert Naive CD4+CD25− Cells to CD25+Foxp3+ Regulatory T Cells and for Expansion of These Cells1 , 2007, The Journal of Immunology.

[29]  石山 宏平 Difference in cytotoxicity against hepatocellular carcinoma between liver and periphery natural killer cells in humans , 2006 .

[30]  G. Bastert,et al.  Metastatic breast cancer: clinical course, prognosis and therapy related to the first site of metastasis , 2000, Breast Cancer Research and Treatment.

[31]  B. Sipos,et al.  Tumor Stroma Interactions Induce Chemoresistance in Pancreatic Ductal Carcinoma Cells Involving Increased Secretion and Paracrine Effects of Nitric Oxide and Interleukin-1β , 2004, Cancer Research.

[32]  S. Wahl,et al.  TGF-β: the missing link in CD4+CD25+ regulatory T cell-mediated immunosuppression , 2003 .

[33]  W. Wold,et al.  Anticancer activity of oncolytic adenovirus vector armed with IFN-α and ADP is enhanced by pharmacologically controlled expression of TRAIL , 2008, Cancer Gene Therapy.

[34]  M. Doucet,et al.  TGF‐β Promotes the Establishment of Renal Cell Carcinoma Bone Metastasis , 2006 .

[35]  P. L. Bergsagel,et al.  Advances in biology of multiple myeloma: clinical applications. , 2004, Blood.

[36]  M. Lotze,et al.  Interleukin-17 augments tumor necrosis factor-alpha-induced elaboration of proangiogenic factors from fibroblasts. , 2004, Immunology letters.

[37]  S. Steigen,et al.  Reduced expression of microenvironmental Th1 cytokines accompanies adenomas–carcinomas sequence of colorectum , 2007, Cancer Immunology, Immunotherapy.

[38]  S. Segal,et al.  CD11b+/Gr-1+ Immature Myeloid Cells Mediate Suppression of T Cells in Mice Bearing Tumors of IL-1β-Secreting Cells1 , 2005, The Journal of Immunology.

[39]  A. Chang,et al.  Cutting Edge: Th17 and Regulatory T Cell Dynamics and the Regulation by IL-2 in the Tumor Microenvironment1 , 2007, The Journal of Immunology.

[40]  K. Korach,et al.  Stromal cell-derived factor 1, a novel target of estrogen receptor action, mediates the mitogenic effects of estradiol in ovarian and breast cancer cells. , 2003, Molecular endocrinology.

[41]  E. Robertson,et al.  IL-2- and IL-15-induced activation of the rapamycin-sensitive mTORC1 pathway in malignant CD4+ T lymphocytes. , 2008, Blood.

[42]  Dafeng Yang,et al.  Downregulation of IFN‐γR in association with loss of Fas function is linked to tumor progression , 2008, International journal of cancer.

[43]  D. Longo,et al.  Ammonium Trichloro(dioxoethylene-o,o′)tellurate (AS101) Sensitizes Tumors to Chemotherapy by Inhibiting the Tumor Interleukin 10 Autocrine Loop , 2004, Cancer Research.

[44]  M. Detmar,et al.  Effects of rIFN alpha, beta, and gamma on the morphology, proliferation, and cell surface antigen expression of human dermal microvascular endothelial cells in vitro. , 1990, The Journal of investigative dermatology.

[45]  M. Büchler,et al.  On the TRAIL to therapeutic intervention in liver disease , 2007, Hepatology.

[46]  Toshikazu Nakamura,et al.  Hepatocyte growth factor and the Met system as a mediator of tumor–stromal interactions , 2006, International journal of cancer.

[47]  D A Hilton,et al.  Overexpression of hypoxia-inducible factor 1alpha in common human cancers and their metastases. , 1999, Cancer research.

[48]  A. Roberts,et al.  Breast cancer cells induce stromal fibroblasts to express MMP-9 via secretion of TNF-α and TGF-β , 2005, Journal of Cell Science.

[49]  T. Blankenstein The role of tumor stroma in the interaction between tumor and immune system. , 2005, Current opinion in immunology.

[50]  P. Allavena,et al.  Increased Survival, Proliferation, and Migration in Metastatic Human Pancreatic Tumor Cells Expressing Functional CXCR4 , 2004, Cancer Research.

[51]  M. Roncarolo,et al.  Differentiation of Tr1 cells by immature dendritic cells requires IL-10 but not CD25+CD4+ Tr cells. , 2005, Blood.

[52]  S. Chow,et al.  Expression of inhibitory natural killer receptors on tumor‐infiltrating CD8+ T lymphocyte lineage in human endometrial carcinoma , 2005, International journal of gynecological cancer : official journal of the International Gynecological Cancer Society.

[53]  Dennis C. Sgroi,et al.  Stromal Fibroblasts Present in Invasive Human Breast Carcinomas Promote Tumor Growth and Angiogenesis through Elevated SDF-1/CXCL12 Secretion , 2005, Cell.

[54]  M. Berger,et al.  Akt pathway activation converts anaplastic astrocytoma to glioblastoma multiforme in a human astrocyte model of glioma. , 2001, Cancer research.

[55]  R. Greil,et al.  Expression of functional interleukin-15 receptor and autocrine production of interleukin-15 as mechanisms of tumor propagation in multiple myeloma. , 2000, Blood.

[56]  L. Liotta,et al.  Metastatic potential correlates with enzymatic degradation of basement membrane collagen , 1980, Nature.

[57]  Xin-Yuan Fu,et al.  Smad4 signalling in T cells is required for suppression of gastrointestinal cancer , 2006, Nature.

[58]  Kathleen M. Smith,et al.  IL-23 stimulates epidermal hyperplasia via TNF and IL-20R2–dependent mechanisms with implications for psoriasis pathogenesis , 2006, The Journal of experimental medicine.

[59]  T. Horikoshi,et al.  Inhibitory effect of human fibroblast interferon (HuIFN‐β) on the growth and invasive potential of cultured human melanoma cells in vitro , 1992, The British journal of dermatology.

[60]  E. Mayhew,et al.  Uveal melanoma expression of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) receptors and susceptibility to TRAIL-induced apoptosis. , 2004, Investigative ophthalmology & visual science.

[61]  C. Bucana,et al.  Constitutive expression of interferon beta in differentiated epithelial cells exposed to environmental stimuli. , 1998, Cancer biotherapy & radiopharmaceuticals.

[62]  S. Chien,et al.  Tumor-derived factors impaired motility and immune functions of dendritic cells through derangement of biophysical characteristics and reorganization of cytoskeleton. , 2007, Cell motility and the cytoskeleton.

[63]  R. Kastelein,et al.  Swords into plowshares: IL-23 repurposes tumor immune surveillance. , 2007, Trends in immunology.

[64]  C. Jobin,et al.  STAT3 regulates NF-κB recruitment to the IL-12p40 promoter in dendritic cells , 2005 .

[65]  C. Dinney,et al.  Interferon-alpha-mediated down-regulation of angiogenesis-related genes and therapy of bladder cancer are dependent on optimization of biological dose and schedule. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[66]  T. Rème,et al.  Bone marrow mesenchymal stem cells are abnormal in multiple myeloma , 2007, Leukemia.

[67]  T. Mcclanahan,et al.  IL-23 drives a pathogenic T cell population that induces autoimmune inflammation , 2005, The Journal of experimental medicine.

[68]  S. Hayward,et al.  Loss of TGF-beta type II receptor in fibroblasts promotes mammary carcinoma growth and invasion through upregulation of TGF-alpha-, MSP- and HGF-mediated signaling networks. , 2005, Oncogene.

[69]  Y. Saga,et al.  Interleukin-10-mediated inhibition of angiogenesis and tumor growth in mice bearing VEGF-producing ovarian cancer. , 2003, Cancer research.

[70]  B. Nathwani,et al.  IL-6 levels and genotype are associated with risk of young adult Hodgkin lymphoma. , 2004, Blood.

[71]  C. Gregory,et al.  Enhanced Apoptotic Cell Clearance Capacity and B Cell Survival Factor Production by IL-10-Activated Macrophages: Implications for Burkitt’s Lymphoma1 , 2005, The Journal of Immunology.

[72]  M. Battaglia,et al.  Tr1 cells: from discovery to their clinical application. , 2006, Seminars in immunology.

[73]  B. Bonavida,et al.  Inhibition of interleukin 10 by rituximab results in down-regulation of bcl-2 and sensitization of B-cell non-Hodgkin's lymphoma to apoptosis. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[74]  A. Mastro,et al.  Metastatic breast cancer induces an osteoblast inflammatory response. , 2008, Experimental cell research.

[75]  N. Munshi,et al.  Multiple myeloma: A prototypic disease model for the characterization and therapeutic targeting of interactions between tumor cells and their local microenvironment , 2007, Journal of cellular biochemistry.

[76]  W. Leonard,et al.  IL-2 and IL-21 confer opposing differentiation programs to CD8+ T cells for adoptive immunotherapy. , 2008, Blood.

[77]  Y. Chang,et al.  KSHV-encoded viral IL-6 activates multiple human IL-6 signaling pathways. , 1999, Human immunology.

[78]  Wan-Wan Lin,et al.  A cytokine-mediated link between innate immunity, inflammation, and cancer. , 2007, The Journal of clinical investigation.

[79]  Hiroshi Yasui,et al.  Perifosine, an oral bioactive novel alkylphospholipid, inhibits Akt and induces in vitro and in vivo cytotoxicity in human multiple myeloma cells. , 2005, Blood.

[80]  Cheng Dong,et al.  Regulation of interleukin-8 expression in melanoma-stimulated neutrophil inflammatory response. , 2007, Experimental cell research.

[81]  J. Votaw,et al.  Silencing of CXCR4 blocks breast cancer metastasis. , 2005, Cancer research.

[82]  Yuka Kanno,et al.  Signaling by IL‐12 and IL‐23 and the immunoregulatory roles of STAT4 , 2004, Immunological reviews.

[83]  R. Schreiber,et al.  The immunobiology of cancer immunosurveillance and immunoediting. , 2004, Immunity.

[84]  J. Soulier,et al.  Phenotypic and functional characterization of bone marrow mesenchymal stem cells derived from patients with multiple myeloma , 2007, Leukemia.

[85]  I. Holen,et al.  Osteoprotegerin (OPG) Produced by Bone Marrow Stromal Cells Protects Breast Cancer Cells from TRAIL-Induced Apoptosis , 2004, Breast Cancer Research and Treatment.

[86]  A. Wong,et al.  Activation of p70S6K induces expression of matrix metalloproteinase 9 associated with hepatocyte growth factor-mediated invasion in human ovarian cancer cells. , 2006, Endocrinology.

[87]  R. Derynck,et al.  TGF-beta induced transdifferentiation of mammary epithelial cells to mesenchymal cells: involvement of type I receptors , 1994, The Journal of cell biology.

[88]  K. Liao,et al.  Interactions of host IL-6 and IFN-γ and cancer-derived TGF-β1 on MHC molecule expression during tumor spontaneous regression , 2008, Cancer Immunology, Immunotherapy.

[89]  D. Farkas,et al.  Induction of potent antitumor immunity by intratumoral injection of interleukin 23-transduced dendritic cells. , 2006, Cancer research.

[90]  H. Murakami,et al.  Th1/Th2 Cells in Patients with Multiple Myeloma , 2004, Hematology.

[91]  N. Restifo,et al.  Assumptions of the tumor 'escape' hypothesis. , 2002, Seminars in cancer biology.

[92]  N. Munshi,et al.  Focus on multiple myeloma. , 2004, Cancer cell.

[93]  C. Bucana,et al.  Modulation of the invasive phenotype of human colon carcinoma cells by organ specific fibroblasts of nude mice. , 1992, Differentiation; research in biological diversity.

[94]  J. Massagué,et al.  Cytostatic and apoptotic actions of TGF-beta in homeostasis and cancer. , 2003, Nature reviews. Cancer.

[95]  Brian Barnett,et al.  Bone Marrow Is a Reservoir for CD4+CD25+ Regulatory T Cells that Traffic through CXCL12/CXCR4 Signals , 2004, Cancer Research.

[96]  B. Sipos,et al.  TRAIL promotes metastasis of human pancreatic ductal adenocarcinoma , 2006, Oncogene.

[97]  T. Wang,et al.  Inflammation, atrophy, and gastric cancer. , 2007, The Journal of clinical investigation.

[98]  A. Rudensky,et al.  A function for interleukin 2 in Foxp3-expressing regulatory T cells , 2005, Nature Immunology.

[99]  L. Liotta,et al.  Signal transduction for chemotaxis and haptotaxis by matrix molecules in tumor cells , 1990, The Journal of cell biology.

[100]  M. Lotze,et al.  Interleukin-17 promotes angiogenesis and tumor growth. , 2003, Blood.

[101]  Brian Bierie,et al.  Tumour microenvironment: TGFβ: the molecular Jekyll and Hyde of cancer , 2006, Nature Reviews Cancer.

[102]  F. Marincola,et al.  Interleukin‐10 and the immune response against cancer: a counterpoint , 2005, Journal of leukocyte biology.

[103]  C. Bucana,et al.  Influence of organ environment on extracellular matrix degradative activity and metastasis of human colon carcinoma cells. , 1990, Journal of the National Cancer Institute.

[104]  R. Bargou,et al.  Signalling and survival pathways in multiple myeloma. , 2006, European journal of cancer.

[105]  M. Lotze,et al.  IL-17 Enhances the Net Angiogenic Activity and In Vivo Growth of Human Non-Small Cell Lung Cancer in SCID Mice through Promoting CXCR-2-Dependent Angiogenesis1 , 2005, The Journal of Immunology.

[106]  Elise C. Kohn,et al.  The microenvironment of the tumour–host interface , 2001, Nature.

[107]  H. Moses,et al.  Induction by transforming growth factor-β1 of epithelial to mesenchymal transition is a rare event in vitro , 2004, Breast Cancer Research.

[108]  Kazuhiro Yoshida,et al.  Production of interleukin 15 by human colon cancer cells is associated with induction of mucosal hyperplasia, angiogenesis, and metastasis. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[109]  Michael Karin,et al.  IKK/NF-κB signaling: balancing life and death – a new approach to cancer therapy , 2005 .

[110]  P. Comoglio,et al.  The Met pathway: master switch and drug target in cancer progression , 2006, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[111]  J. Ritz,et al.  IL-15 is produced by a subset of human melanomas, and is involved in the regulation of markers of melanoma progression through juxtacrine loops , 1998, Oncogene.

[112]  A. Verma,et al.  Transforming Growth Factor-β Signaling in Normal and Malignant Hematopoiesis , 2007 .

[113]  M. Karin Nuclear factor-κB in cancer development and progression , 2006, Nature.

[114]  D. W. Kim,et al.  CXC chemokine receptor 4 expression and function in human anaplastic thyroid cancer cells. , 2003, The Journal of clinical endocrinology and metabolism.

[115]  Geoffrey C Gurtner,et al.  Progenitor cell trafficking is regulated by hypoxic gradients through HIF-1 induction of SDF-1 , 2004, Nature Medicine.

[116]  T. Mcclanahan,et al.  Involvement of chemokine receptors in breast cancer metastasis , 2001, Nature.

[117]  L. Coussens,et al.  Paradoxical roles of the immune system during cancer development , 2006, Nature Reviews Cancer.

[118]  S. Sakaguchi Naturally arising Foxp3-expressing CD25+CD4+ regulatory T cells in immunological tolerance to self and non-self , 2005, Nature Immunology.

[119]  H. Alexander,et al.  Journal of Translational Medicine Interleukin-1 and Cancer Progression: the Emerging Role of Interleukin-1 Receptor Antagonist as a Novel Therapeutic Agent in Cancer Treatment , 2022 .

[120]  Luzhe Sun,et al.  Transforming growth factor-beta signaling in prostate stromal cells supports prostate carcinoma growth by up-regulating stromal genes related to tissue remodeling. , 2007, Cancer research.

[121]  B. Sheu,et al.  Reversed CD4/CD8 ratios of tumor‐infiltrating lymphocytes are correlated with the progression of human cervical carcinoma , 1999, Cancer.

[122]  Jack D Bui,et al.  Cancer immunosurveillance, immunoediting and inflammation: independent or interdependent processes? , 2007, Current opinion in immunology.

[123]  K. Pienta,et al.  Expression of CXCR4 and CXCL12 (SDF‐1) in human prostate cancers (PCa) in vivo , 2003, Journal of cellular biochemistry.

[124]  S. Chow,et al.  Up-regulation of inhibitory natural killer receptors CD94/NKG2A with suppressed intracellular perforin expression of tumor-infiltrating CD8+ T lymphocytes in human cervical carcinoma. , 2005, Cancer research.

[125]  Yoichiro Iwakura,et al.  Interleukin-1beta-driven inflammation promotes the development and invasiveness of chemical carcinogen-induced tumors. , 2007, Cancer research.

[126]  M. Bar‐eli,et al.  Regulation of tumor growth and metastasis by interleukin-10: the melanoma experience. , 1999, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research.

[127]  P. Gariglio,et al.  Interleukin‐10 promotes B16‐melanoma growth by inhibition of macrophage functions and induction of tumour and vascular cell proliferation , 2002, Immunology.

[128]  E. Mayhew,et al.  Expression and possible function of IL-2 and IL-15 receptors on human uveal melanoma cells. , 2004, Investigative ophthalmology & visual science.

[129]  Brian Bierie,et al.  A delicate balance: TGF‐β and the tumor microenvironment , 2007, Journal of cellular biochemistry.

[130]  M. Roncarolo,et al.  Differentiation of Tr 1 cells by immature dendritic cells requires IL-10 but not CD 25 CD 4 Tr cells , 2005 .

[131]  B. Sheu,et al.  Current concepts of tumor-infiltrating lymphocytes in human malignancies. , 2005, Journal of reproductive immunology.

[132]  Brian Bierie,et al.  TGF-beta and cancer. , 2006, Cytokine & growth factor reviews.

[133]  R. J. Kelleher,et al.  Characterization of Human Lung Tumor-Associated Fibroblasts and Their Ability to Modulate the Activation of Tumor-Associated T Cells1 , 2007, The Journal of Immunology.

[134]  S. Chow,et al.  Increased expression and activation of gelatinolytic matrix metalloproteinases is associated with the progression and recurrence of human cervical cancer. , 2003, Cancer research.

[135]  T. Hirano,et al.  IL-6 in autoimmune disease and chronic inflammatory proliferative disease. , 2002, Cytokine & growth factor reviews.

[136]  T. Mcclanahan,et al.  IL-23 promotes tumour incidence and growth , 2006, Nature.

[137]  Lieve Moons,et al.  CXCL12 and vascular endothelial growth factor synergistically induce neoangiogenesis in human ovarian cancers. , 2005, Cancer research.

[138]  H. Moch,et al.  Chemokine receptor CXCR4 downregulated by von Hippel–Lindau tumour suppressor pVHL , 2003, Nature.